Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Entrada Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Entrada Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $134.75M, down 4.9% year over year. For fiscal 2025 it was $142.27M, up 13.5% from the year before. The highest annual figure on record is $142.27M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.27M | +13.5% |
| FY2024 | Dec 31, 2024 | $125.31M | +25.5% |
| FY2023 | Dec 31, 2023 | $99.88M | +50.0% |
| FY2022 | Dec 31, 2022 | $66.61M | +85.4% |
| FY2021 | Dec 31, 2021 | $35.93M | +70.2% |
| FY2020 | Dec 31, 2020 | $21.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $32.37M | -15.6% |
| Q2 FY2026 | Jun 30, 2026 | $35.37M | -6.6% |
| Q1 FY2026 | Mar 31, 2026 | $33.05M | +3.1% |
| Q4 FY2025 | Dec 31, 2025 | $33.96M | +1.6% |
| Q3 FY2025 | Sep 30, 2025 | $38.36M | +22.7% |
| Q2 FY2025 | Jun 30, 2025 | $37.88M | +18.2% |
| Q1 FY2025 | Mar 31, 2025 | $32.07M | +12.1% |
| Q4 FY2024 | Dec 31, 2024 | $33.41M | +18.1% |
| Q3 FY2024 | Sep 30, 2024 | $31.26M | +40.9% |
| Q2 FY2024 | Jun 30, 2024 | $32.04M | +21.8% |
| Q1 FY2024 | Mar 31, 2024 | $28.61M | +23.8% |
| Q4 FY2023 | Dec 31, 2023 | $28.29M | +80.4% |
| Q3 FY2023 | Sep 30, 2023 | $22.19M | +17.1% |
| Q2 FY2023 | Jun 30, 2023 | $26.30M | +61.9% |
| Q1 FY2023 | Mar 31, 2023 | $23.10M | +47.0% |
| Q4 FY2022 | Dec 31, 2022 | $15.69M | +26.9% |
| Q3 FY2022 | Sep 30, 2022 | $18.96M | +80.3% |
| Q2 FY2022 | Jun 30, 2022 | $16.25M | +137.9% |
| Q1 FY2022 | Mar 31, 2022 | $15.72M | +152.6% |
| Q4 FY2021 | Dec 31, 2021 | $12.36M | +85.7% |
| Q3 FY2021 | Sep 30, 2021 | $10.51M | +84.4% |
| Q2 FY2021 | Jun 30, 2021 | $6.83M | – |
| Q1 FY2021 | Mar 31, 2021 | $6.22M | – |
| Q4 FY2020 | Dec 31, 2020 | $6.66M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.70M | – |
See a number that looks wrong?